BeOne Medicines Ltd. - Sponsored ADR

ONC Healthcare Biotechnology

BeOne Medicines Ltd. - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $5.3 billion, up 40.2% from fiscal 2024.

Revenue
+33.8%
EPS
+143.7%
Free cash flow
+33.6%
Total debt
+491.3%

Quarter to September 2026, against a year earlier

407.83 20.58 +5.31%
Market cap
$40.4B
P/E
65.9×
Fwd P/E
48.8×
Dividend yield
—
F-score
7/9
Altman Z
5.25
Beneish M
−2.73
Dividend safety
n/a

BeOne Medicines Ltd. - Sponsored ADR (ONC) Operating cash flow

Alert me on Operating cash flow

BeOne Medicines Ltd. - Sponsored ADR's operating cash flow for fiscal 2025 was $1.1B, compared with −$140.6M in fiscal 2024. Over the twelve months to 30 September 2026 it was $1.6B. Over the past ten years it has ranged from −$1.5B (fiscal 2022) to $1.1B (fiscal 2025) — the current reading is the highest in ten years. Operating cash flow has risen for 3 consecutive fiscal years. BeOne Medicines Ltd. - Sponsored ADR ranks 6th of 603 Biotechnology companies by operating cash flow.

Operating cash flow, annual

Embed this chart

Annual newest first

Period Operating cash flow Change
FY2025 $1.1B —
FY2024 −$140.6M —
FY2023 −$1.2B —
FY2022 −$1.5B —
FY2021 −$1.3B —
FY2020 −$1.3B —
FY2019 −$750.3M —
FY2018 −$547.7M —
FY2017 $12.8M —
FY2016 −$89.5M —

Quarterly newest first

Period Operating cash flow Change
Sep 2026 $508.7M 9.91%
Jun 2026 $462.8M 129.87%
Mar 2026 $201.3M (51.76%)
Dec 2025 $417.3M 3.68%
43 more quarters

Against its own ten years

Low −$1.5B High $1.1B
Ten-year median −$547.7M
Current reading's percentile 100

Operating cash flow against peers

What Operating cash flow is

Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.

Reported line item

The full definition of Operating cash flow →

More on ONC